Trial Outcomes & Findings for PrEP4Her: Developing a Novel Strategy to Implement PrEP Into Women's Healthcare (NCT NCT07209722)

NCT ID: NCT07209722

Last Updated: 2026-01-26

Results Overview

Number of participants receiving a new PrEP prescription during the recruitment period

Recruitment status

COMPLETED

Target enrollment

1377 participants

Primary outcome timeframe

8 months

Results posted on

2026-01-26

Participant Flow

Participant milestones

Participant milestones
Measure
Sexual Health-PRO
Patients seen during routine GYN clinic visit. PrEP acronym (pre-exposure prophylaxis): Tracked PrEP prescriptions over 8 months among patients who completed the survey
Post Visit (Fidelity) Survey
Patients who completed the survey outside of clinic visit PrEP acronym (pre-exposure prophylaxis): Tracked PrEP prescriptions over 8 months among patients who completed the survey
Overall Study
STARTED
1135
242
Overall Study
COMPLETED
1135
242
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

PrEP4Her: Developing a Novel Strategy to Implement PrEP Into Women's Healthcare

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Sexual Health-PRO
n=1135 Participants
Patients seen during routine GYN clinic visit. PrEP acronym (pre-exposure prophylaxis): Tracked PrEP prescriptions over 8 months among patients who completed the survey
Post Visit (Fidelity) Survey
n=242 Participants
Patients who completed the survey outside of clinic visit PrEP acronym (pre-exposure prophylaxis): Tracked PrEP prescriptions over 8 months among patients who completed the survey
Total
n=1377 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=25 Participants
0 Participants
n=25 Participants
0 Participants
n=50 Participants
Age, Categorical
Between 18 and 65 years
1135 Participants
n=25 Participants
242 Participants
n=25 Participants
1377 Participants
n=50 Participants
Age, Categorical
>=65 years
0 Participants
n=25 Participants
0 Participants
n=25 Participants
0 Participants
n=50 Participants
Age, Continuous
35 year
STANDARD_DEVIATION 11.5 • n=25 Participants
35 year
STANDARD_DEVIATION 11.5 • n=25 Participants
35 year
STANDARD_DEVIATION 11.5 • n=50 Participants
Sex: Female, Male
Female
1135 Participants
n=25 Participants
242 Participants
n=25 Participants
1377 Participants
n=50 Participants
Sex: Female, Male
Male
0 Participants
n=25 Participants
0 Participants
n=25 Participants
0 Participants
n=50 Participants
Race/Ethnicity, Customized
Black
727 Participants
n=25 Participants
100 Participants
n=25 Participants
827 Participants
n=50 Participants
Race/Ethnicity, Customized
White
235 Participants
n=25 Participants
140 Participants
n=25 Participants
375 Participants
n=50 Participants
Race/Ethnicity, Customized
Hispanic
143 Participants
n=25 Participants
2 Participants
n=25 Participants
145 Participants
n=50 Participants
Race/Ethnicity, Customized
Asian
30 Participants
n=25 Participants
0 Participants
n=25 Participants
30 Participants
n=50 Participants
Region of Enrollment
United States
1135 Participants
n=25 Participants
242 Participants
n=25 Participants
1377 Participants
n=50 Participants

PRIMARY outcome

Timeframe: 8 months

Population: All women who received care at the GYN clinic during the study period received the PrEP4Her intervention as a component of their routine standard of gynecologic care.

Number of participants receiving a new PrEP prescription during the recruitment period

Outcome measures

Outcome measures
Measure
Sexual Health-PRO
n=1135 Participants
Patients seen during routine GYN clinic visit. PrEP acronym (pre-exposure prophylaxis): Tracked PrEP prescriptions over 8 months among patients who completed the survey
Post Visit (Fidelity) Survey
n=242 Participants
Patients who completed the survey outside of clinic visit PrEP acronym (pre-exposure prophylaxis): Tracked PrEP prescriptions over 8 months among patients who completed the survey
PrEP Prescriptions
11 Participants
0 Participants

Adverse Events

Sexual Health-PRO

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Post Visit (Fidelity) Survey

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Bernadette Johnson

UAB

Phone: 205-934-7329

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place